
News|Articles|December 1, 2012
Aubagio (Teriflunomide)
New molecular entity: FDA approved teriflunomide (Aubagio, Genzyme, a Sanofi-Aventis company), a pyrimidine synthesis inhibitor, for the treatment of patients with relapsing forms of multiple sclerosis (MS).
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Quadruplet treatments for multiple myeloma are rising but access varies | ASH 2025
2
ACIP votes to end universal birth-dose for hepatitis B vaccine with updated guidance for parents and doctors
3
AstraZeneca’s Imfinzi gains landmark FDA approval for early gastric and gastroesophageal cancers
4
Transplant-fueled hybrid immune systems may help reverse Type 1 diabetes
5





















































